Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 5
2003 6
2004 3
2005 8
2006 3
2007 3
2008 8
2009 5
2010 7
2011 9
2012 7
2013 8
2014 7
2015 11
2016 6
2017 11
2018 5
2019 16
2020 15
2021 14
2022 14
2023 3
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Results by year

Filters applied: . Clear all
Page 1
Empagliflozin in Patients with Chronic Kidney Disease.
The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. The EMPA-KIDNEY Collaborative Group, et al. N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4. N Engl J Med. 2023. PMID: 36331190 Free PMC article. Clinical Trial.
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Das Pradhan A, et al. N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. N Engl J Med. 2022. PMID: 36342113 Clinical Trial.
Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.
Yabe D, Nakamura J, Kaneto H, Deenadayalan S, Navarria A, Gislum M, Inagaki N; PIONEER 10 Investigators. Yabe D, et al. Among authors: nakamura j. Lancet Diabetes Endocrinol. 2020 May;8(5):392-406. doi: 10.1016/S2213-8587(20)30074-7. Lancet Diabetes Endocrinol. 2020. PMID: 32333876 Clinical Trial.
MYCL-mediated reprogramming expands pancreatic insulin-producing cells.
Hirano M, So Y, Tsunekawa S, Kabata M, Ohta S, Sagara H, Sankoda N, Taguchi J, Yamada Y, Ukai T, Kato M, Nakamura J, Ozawa M, Yamamoto T, Yamada Y. Hirano M, et al. Among authors: nakamura j. Nat Metab. 2022 Feb;4(2):254-268. doi: 10.1038/s42255-022-00530-y. Epub 2022 Feb 10. Nat Metab. 2022. PMID: 35145326
[Myo-inositol].
Nakashima E, Nakamura J. Nakashima E, et al. Among authors: nakamura j. Nihon Rinsho. 2002 Aug;60 Suppl 8:456-62. Nihon Rinsho. 2002. PMID: 12355790 Review. Japanese. No abstract available.
Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry).
Ueki K, Tanizawa Y, Nakamura J, Yamada Y, Inagaki N, Watada H, Shimomura I, Nishimura R, Miyoshi H, Abiko A, Katagiri H, Hayashi M, Shimada A, Naruse K, Fujimoto S, Fujiwara M, Shikata K, Okada Y, Araki E, Yamazaki T, Kadowaki T; J-BRAND Registry Group. Ueki K, et al. Among authors: nakamura j. BMJ Open Diabetes Res Care. 2021 Jan;9(1):e001787. doi: 10.1136/bmjdrc-2020-001787. BMJ Open Diabetes Res Care. 2021. PMID: 33441417 Free PMC article.
153 results